Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
about
Mapping of the gene for the human telomerase reverse transcriptase, hTERT, to chromosome 5p15.33 by fluorescence in situ hybridizationPharmacologic resistance in colorectal cancer: a reviewAssessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsMolecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines.Identification of genetic changes associated with drug resistance by reverse in situ hybridizationTopoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.Thymidylate synthase predictive power is overcome by irinotecan combination therapy with S-1 for gastric cancer.Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutationsTopoisomerase I as a biomarker: detection of activity at the single molecule level.Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.Predictive biomarkers with potential of converting conventional chemotherapy to targeted therapy in patients with metastatic colorectal cancer.TOP1 gene copy numbers in colorectal cancer samples and cell lines and their association to in vitro drug sensitivity.A quantitative RT-PCR method to determine topoisomerase I mRNA levels in human tissue samples.Elevations of DNA topoisomerase I in invasive carcinoma of the breast.DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer.Expression of drug pathway proteins is independent of tumour type.Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer.
P2860
Q24551148-C2C2ACDD-E142-4684-9824-C5EAEBB0E948Q26769850-580416B9-63AA-4977-9F3B-246E2CFE3082Q27852685-71DC5925-6340-4D10-AC95-205D69990960Q33734562-A4965644-E6A2-4D1F-8813-17EEC16FE486Q34008793-541CCE5B-F867-4F80-8664-7973E2E332B4Q35902206-F60A9D4C-4529-4B76-9B4F-C7B30441DBE6Q36116003-BA305F9D-4670-472F-ACFF-BEB4BB81F7B1Q36246729-F3391236-144F-4D5C-B890-55B11C48B8BCQ36695672-7E2F1D65-FC9A-4C6D-9D13-7140312B7B45Q36749303-64BD3DE5-4C1A-43BB-86FB-CCEC5BA58415Q37588708-DED772C5-5CDF-4504-9144-00047AA5A906Q37923365-6C019CDC-8F55-4122-B9B2-66F966E4BB4AQ37969770-C37228D3-6CCF-468E-BE3F-CFCC6258D87DQ39428021-0A7AC154-618D-4512-AA0C-D1001DAA944DQ40365203-87459B64-91AA-4E75-8064-CFE8A2C911A5Q43685655-398C8BB8-183E-4737-95BB-98BF4D8C3E88Q46158806-5C2D19C4-F32A-4FCB-A4F5-15E6DAEB65D2Q46969619-9AC8AA17-DF27-4CBF-B9C6-E4C3BB23D20EQ53552603-7D0CF1F1-3FDE-403F-9297-1A17518572F8
P2860
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Variation in topoisomerase I g ...... or intrinsic drug sensitivity.
@ast
Variation in topoisomerase I g ...... or intrinsic drug sensitivity.
@en
type
label
Variation in topoisomerase I g ...... or intrinsic drug sensitivity.
@ast
Variation in topoisomerase I g ...... or intrinsic drug sensitivity.
@en
prefLabel
Variation in topoisomerase I g ...... or intrinsic drug sensitivity.
@ast
Variation in topoisomerase I g ...... or intrinsic drug sensitivity.
@en
P2860
P356
P1476
Variation in topoisomerase I g ...... or intrinsic drug sensitivity.
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1996.394
P407
P577
1996-08-01T00:00:00Z